Clinical and Molecular Hepatology

Article	Citations
Preface	486
An editorial on “Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation” by Hong et al.	460
Contemporary Trends in Extrahepatic Mortality of Chronic Liver Disease in the United States from 2014 to 2023	304
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future	231
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	214
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus	213
Letter “GLP-1 RA and Reduced Liver and Non-Liver Complications in Adults with T2D and MASLD: A Target Trial Emulation Study”	156
Approaches to quantifying hepatitis B virus covalently closed circular DNA	140
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation	107
Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis	105
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials	103
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)	103
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases	95
Letter"Novel Genetic Modulators of MASLD Identified Through Genome-Wide Interaction with BMI"	95
Unveiling etiology-specific blood biomarkers in hepatocellular carcinoma: A gateway to personalized medicine: Editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific sign	78
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer	73
Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?	72
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity	72
Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity	72
Targeting the ASB3-CPT1A axis—a new player in combating metabolic dysfunction-associated steatotic liver disease	66
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study	65
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 c	63
Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”	61
Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease	60
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A	57

Toward hepatitis C virus elimination using artificial intelligence	56
Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	56
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease	55
HCC Surveillance After Curative Treatment: A New Frontier for Abbreviated MRI Editorial on: “Non-contrast MRI for Detection of Late Recurrent Hepatocellular Carcinoma After Curative Treatment: Compari	55
Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis	54
Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial	52
Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma	50
Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target	49
Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma	49
Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023	47
2025 KASL clinical practice guidelines for management of hepatitis C	47
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment	47
Liver organoids: Current advances and future applications for hepatology	46
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on “Antiviral therapy for chronic hepatitis B with mildly elevate	45
Hard-to-treat autoimmune hepatitis and primary biliary cholangitis: The dawn of a new era of pharmacological treatment	45
Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma	45
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review	43
Correspondence to the letter titled “Revisiting the Role of Non-Contrast MRI in Recurrent HCC: Bridging Diagnostic Performance and Real-World Applicability”	43
What is new in the 2024 Chinese guidelines for fatty liver disease?	43
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunothe	42
Chronic hepatitis B, extrahepatic malignancies and the use of antiviral drugs	41
Correspondence to letter to the editor on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”	41
Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”	38
Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology	38
Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?	37
A decade of liver organoids: Advances in disease modeling	37
Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation	37
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program	36
Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”	36
Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”	34
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease	34
Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C	33
Stroma-tology: Predicting recurrence in cholangiocarcinoma: Editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	33
Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies	33
Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”	33
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality	32
Plasma Lipidomic and Fungal Signatures Predict Early Mortality in Acute Liver Failure	31
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease	31
Reply to correspondence on: Methodological Concerns Regarding GLP-1RA Effects on MASLD Outcomes	31
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly	30
Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study	29
Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies	29
Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated	29
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”	28
Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma	28
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”	28
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?	28
Reappraisal of transarterial radioembolization for liver-confined hepatocellular carcinoma with portal vein tumor thrombosis: Editorial on “Transarterial radioembolization versus tyrosine kinase inhib	27
The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The	27
Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity	26

Rethinking ACLF Prognosis: Can Machine Learning Outperform Conventional Scores? Editorial on: Predictive Machine Learning Model in ICU Patients with Acute-on-Chronic Liver Failure and Two or More Orga	26
Interaction between sarcopenia and nonalcoholic fatty liver disease	26
Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma	26
Immunopathogenesis of liver fibrosis in steatotic liver disease	26
Global incidence and prevalence of nonalcoholic fatty liver disease	25
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression	25
Metabolic Health in Antiviral Era of Chronic Hepatitis B	25
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?	25
Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis	25
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences	25
Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways	25
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients	24
Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score? Editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dys	24
Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”	24
Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load	24
Development of risk scores for prognosis prediction among patients with early-stage hepatocellular carcinoma	24
Pediatric metabolic dysfunction-associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation	24
Acute-on-chronic liver failure: Terminology, mechanisms and management	24
Correspondence on Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	23
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma	23
Gut microbiome and metabolome signatures in liver cirrhosis-related complications	23
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association	23
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohe	23
Assessment of the postoperative prognosis in patients with hepatocellular carcinoma using vibration-controlled transient elastography: A systemic review and meta-analysis	23
Mendelian randomization does not support the effects of G CSF on decompensated liver disease	23
Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?	22
A new Korean nomenclature for steatotic liver disease	22
Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”	22
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise	22
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial	21
Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	21
Decreasing performance of HCC prediction models during antiviral therapy for hepatitis B: what else to keep in mind: Editorial on “Hepatocellular carcinoma prediction model performance decreases with	21
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy	21
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma	21
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation	20
Regulation of Hepatitis B Virus cccDNA by Metabolic Pathways	20
Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”	20
KASL clinical practice guidelines for management of chronic hepatitis B	19
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systemati	19
Letter to the editor: Clarifying Residual Drug Effects and Subgroup Outcomes in TDF-to-BSV Switch Trials	19
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound	19
Reply to Correspondence to “Call for Preemptive Treatment of Cytomegalovirus in Patients with Cirrhosis and Acute Decompensation”	19
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma	19
The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults	18
Screening strategy for non-alcoholic fatty liver disease	18
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications	18
Stratifying Cholangiocarcinoma: Tumor Microenvironment, Molecular Drivers, and Novel Immunotherapeutic Approaches	18
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals	18
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	17
Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis	17
A non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: the Baveno VI-SSM combined model.	16
Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications	16
JCAD, a new potential therapeutic target in cholestatic liver disease	16
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”	16
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences	16
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes	16
Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey	16
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease	16
Reply to correspondence on “A Novel Link Between Tumor Cell Metabolism and Patient Prognosis: Editorial on ‘Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and On	16
Clinical implications of residual changes following HCV clearance	16
Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis	16
Evidence-based hyponatremia management in liver disease	15
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agon	15
Harmonized ACLF Prognostication with Explainable Machine Learning Models: Traversing from Counts to Composition	15
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues	15
From past to pandemic: Health disparities in US hepatobiliary cancer mortality before and during COVID-19: Editorial on “Burden of mortality from hepatocellular carcinoma and biliary tract cancers by	14
Surgical resection versus ablation for early hepatocellular carcinoma: The debate is still open	14
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?	14
Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”	14
Global inequality in the burden of hepatitis B from 1990 to 2021: Findings from the global burden of disease study 2021: Letter to the editor on “Comprehensive approach to controlling chronic hepatiti	14
Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients	14
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic	14
Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review	13
Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”	13
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance	13
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis: Editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and	13
Roles of X-box binding protein 1 in liver pathogenesis	13
Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization	13
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective	12
Non-alcoholic fatty liver disease: Definition and subtypes	12

Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”	12
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults	12
Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease	12
Management of refractory ascites	12
Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]	12
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”	12
Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma	12
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease	12
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs	12
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”	12
Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults	12
Plasma Exchange and Abrogation of Monocyte Activation in Wilson’s Disease	12
Correspondence to editorial on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”	11
Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunctionassociated steatotic liver disease”: Rethinking first-line screening in MASLD: beyond the limitations of Fi	11
Longitudinal profile of plasma pregenomic RNA in patients with chronic hepatitis B infection on long-term nucleoside analogues and its interaction with clinical parameters	11
Congratulatory remarks	11
The impact of ischemia-free liver transplantation on improving the prognosis of recipients using functionally marginal liver grafts: Editorial on “Ischemia-free liver transplantation improves the prog	11
Letter to the editor on “HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study. ”	10
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis	10
Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer	10
Early oxidative protein modifications and gut damage/leakiness contribute to drug-induced acute liver failure	10
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis	10
The use of transient elastography for predicting hepatocellular carcinoma in chronic hepatitis B patients: Editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma developme	10
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives	9
Comment on “High Steatosis-Associated Fibrosis Estimator Scores Predict Hepatocellular Carcinoma in Viral and Non-Viral Hepatitis and Metabolic Dysfunction-Associated Steatotic Liver Disease”	9
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD	9
Re: “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”	9
Acute hepatitis C virus infection: clinical update and remaining challenges	9
Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”	9
Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles	9
Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma	9
Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”	9
Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	9
Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation	9
Correspondence: Response to Editorial on “Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression”	8
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response	8
Integrative Multi-Omics Profiling Identifies Infiltrative HCC as an Immunotherapy-Resistant Subtype with Distinct Molecular Features	8
The latest global burden of liver cancer: A past and present threat	8
Hepatorenal syndrome: Current concepts and future perspectives	8
Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area	8
Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults	7
Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma	7
UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL	7
Bridging the gap: The GOLM1-OPN-ABCG5 axis in MASH and gallstone disease: Editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	7
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials	7
Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]	7
Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigen	7
Distinct TIME Modulation by Anti-PD-1/PD-L1, VEGF, and CTLA-4 Blockade Provides a Rationale for Triplet Therapy in HCC	7
GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”	7
Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan	7
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?	7
RISK STRATIFICATION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: THE KASL PATHWAY	6
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”	6
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis	6
Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”	6
Correspondence to editorial on “Integrated molecular characterization of sarcomatoid hepatocellular carcinoma”	6
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology	6
Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in	6
Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”	6
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antiv	6
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis	6
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”	6
Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization	6
Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis	6
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”	6
Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”	6
Correspondence to editorial on “Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis”	6
“Surrogates Without Substance?” Questioning the Evidence for Histologic Improvement With HTD1801	6
Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes	5
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations	5
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective	5
Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage	5
Waiting for the changes after the adoption of steatotic liver disease	5
The gene expression signature of metabolic dysfunction- associated steatotic liver disease from a multiomics perspective	5
Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”	5
MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation	5
The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls	5
Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: In	5
Correspondence to editorial on “Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging”	5
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma	5
Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”	5
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply	5
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future	5
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection	5
KASL clinical practice guidelines for management of autoimmune hepatitis 2022	5
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease	5
Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness	5
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?	5
HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C a	5
Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]	4
Correspondence on editorial regarding “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”	4
Reply to "Correspondence to Economic and Clinical Considerations for NC-MRI in Late HCC Recurrence Surveillance”	4
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”	4
From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically sign	4
Epidemiology and updated management for autoimmune liver disease	4